F Fuzkk Atlas of India
#80FUZKK atlas leaders 1–100

Eli Lilly and Company India Pvt Ltd

Haryana · Delhi NCR–Haryana–Chandigarh

Peptides and metabolic medicines

Manufacturing profile

Peptides and metabolic medicines

State / territory: Haryana

Pharmaceutical cluster: Delhi NCR–Haryana–Chandigarh

Selection basis

The company is placed in positions 1–100 as a major Indian manufacturer, exporter, API/CDMO, generics, vaccine or biopharma participant.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Representative manufacturing and QC chain

  1. 1Peptide synthesis or recombinant upstream
  2. 2Chromatography and UF/DF
  3. 3HPLC/LC-MS and CE peptide mapping
  4. 4Sterile filtration and cartridge/vial filling
  5. 5Particles, sterility, endotoxin and cold-chain release

Relevant FUZKK packages

India: national essential medicines QC packagePeptides, GLP-1 and Obesity QC Suite

Product/API utilities

Insulin Analog Impurity CheckerHuman Insulin Quality CheckerGLP1 Injectable Release Checker

Lumex — instrumental QC

CE Peptide Map ValidatorCE Peptide Map FingerprintInsulinHumanHPLCChecker

LabEx — laboratory QC

LC-MS Confirmation Quality CheckerBacterial Endotoxins LAL Quality CheckerSterility Test Membrane Filtration Quality Checker

Medical Devices — equipment and software lifecycle

Supplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Licence status, GMP status and the actual site portfolio must be rechecked through CDSCO and the relevant State Drug Controller.

Methodology